Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
| ▸ | CTSG | P08311 | 1/20 | 0.46 |
| ▸ | CTRC | Q99895 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.40 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | BLM | P54132 | 2/20 | 0.40 |
| ▸ | GMNN | O75496 | 1/20 | 0.40 |
| ▸ | THPO | P40225 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.40 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1101098 | 0.85 | ALDH1A1 (0.42) | KMT2AMEN1F2ELANECTSG | |
| SCHEMBL11771044 | 0.78 | ALDH1A1 (0.55) | KMT2AMEN1F2ELANECTSG | |
| SCHEMBL20243779 | 0.78 | KMT2A (0.41) | KMT2AMEN1F2ELANECTSG | |
| SCHEMBL2728279 | 0.77 | HPGD (0.49) | KMT2AMEN1ALDH1A1MAPTNPSR1 | |
| SCHEMBL13753310 | 0.75 | F2 (0.42) | F2ELANECTSGCTRCALDH1A1 | |
| SCHEMBL11499891 | 0.75 | MGLL (0.48) | KMT2AMEN1ALDH1A1MAPTNPSR1 | |
| SCHEMBL6232792 | 0.73 | MGLL (0.52) | KMT2AMEN1ALDH1A1MAPTNPSR1 | |
| SCHEMBL6235090 | 0.73 | MEN1 (0.42) | KMT2AMEN1ALDH1A1MAPTPOLB | |
| SCHEMBL6857906 | 0.70 | F2 (0.62) | KMT2AMEN1F2ELANECTSG | |
| SCHEMBL5675960 | 0.69 | MEN1 (0.39) | KMT2AMEN1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023133640-A1 | ELECTRODE MATERIAL COMPRISING AN ORGANIC LAYER, PRODUCTION METHODS, AND ELECTROCHEMICAL USES | HYDRO-QUéBEC (CA) | 2023-07-20 | — | — | WO | claimed |
| EP-0194226-B1 | A PHARMACEUTICAL COMPOSITION CONTAINING AN IMIDAZOLIDINETRIONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1990-02-07 | — | — | EP | claimed |
| EP-0194226-A1 | A pharmaceutical composition containing an imidazolidinetrione derivative or pharmaceutically acceptable salt thereof | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1986-09-10 | — | — | EP | claimed |
| US-20230387464-A1 | Nonaqueous Electrolytic Solution and Nonaqueous Electrolytic Solution Battery | MU IONIC SOLUTIONS CORPORATION (JP) | 2023-11-30 | — | — | US | disclosed |
| US-20230387464-A1 | Nonaqueous Electrolytic Solution and Nonaqueous Electrolytic Solution Battery | MU IONIC SOLUTIONS CORPORATION (JP) | 2023-11-30 | — | — | US | disclosed |
| WO-2023133640-A1 | ELECTRODE MATERIAL COMPRISING AN ORGANIC LAYER, PRODUCTION METHODS, AND ELECTROCHEMICAL USES | HYDRO-QUéBEC (CA) | 2023-07-20 | — | — | WO | disclosed |
| US-7737283-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2010-06-15 | — | — | US | disclosed |
| US-20090312349-A1 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC | 2009-12-17 | — | — | US | disclosed |
| US-20090143354-A1 | P2X7 Receptor Antagonists and Their Use | ASTRAZENECA AB (SE) | 2009-06-04 | — | — | US | disclosed |
| US-7531566-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2009-05-12 | — | — | US | disclosed |
| US-20090105230-A1 | Anti-inflammatory medicaments | FLYNN DANIEL L | 2009-04-23 | — | — | US | disclosed |
| US-6451831-B1 | TREATMENT WITH HYDANTOIN DERIVATIVE | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2002-09-17 | — | — | US | disclosed |
| US-6251929-B1 | ADMINISTERING TO A PATIENT A HYDANTOIN DERIVATIVES AND SALTS AS THERAPEUTIC AND PREVENTIVE AGENTS FOR INTRACTABLE VASCULITIS SUCH AS MALIGNANT RHEUMATOID ARTHRITIS(MRA), PERIARTERITIS NODOSA, WEGENER'S GRANULOMATOSIS ETC. | NIPPON ZOKI PHARMACEUTICALS CO., LTD. (JP) | 2001-06-26 | — | — | US | disclosed |
| EP-0780125-B1 | Use of hydantoin derivatives for the preparation of a medicament for the treatment of dieases associated with the presence of active oxygen and free radicals | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2001-04-18 | — | — | EP | disclosed |
| US-6197806-B1 | USING A HYDANTOIN DERIVATIVE | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2001-03-06 | — | — | US | disclosed |
| EP-1018339-A1 | Therapeutic agent for intractable vasculitis | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2000-07-12 | — | — | EP | disclosed |
| EP-0780125-A2 | Pharmaceutical composition containing a hydantoin derivative and use of said derivative | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 1997-06-25 | — | — | EP | disclosed |
| EP-0194226-B1 | A PHARMACEUTICAL COMPOSITION CONTAINING AN IMIDAZOLIDINETRIONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1990-02-07 | — | — | EP | disclosed |
| US-4683240-A | HYPOGLYCEMIC, HYPOUPIDEMIC | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 1987-07-28 | — | — | US | disclosed |
| EP-0194226-A1 | A pharmaceutical composition containing an imidazolidinetrione derivative or pharmaceutically acceptable salt thereof | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1986-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105230-A1 | Anti-inflammatory medicaments | MIF, PTGES2, TNF | KMT2A 3925/4885MEN1 4863/4885F2 1815/4885 |
| US-20090312349-A1 | ANTI-INFLAMMATORY MEDICAMENTS | ABL2, ABL1, PTK2 | KMT2A 2977/4885MEN1 4734/4885F2 2388/4885 |
| US-20090143354-A1 | P2X7 Receptor Antagonists and Their Use | P2RX7, P2RX1, P2RX2 | KMT2A 3924/4885MEN1 4479/4885F2 4163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.